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Abstract
Background: Joint hypermobility syndrome describes a disorder in which musculoskeletal pain occurs in a generalized
joint hypermobility substrate. The clinical picture comprises variable manifestations which involve mainly but not
exclusively the musculoskeletal system, and evolve over the person’s lifetime.
Case presentation: Describing the case of a 20-year-old female with generalized arthro-myalgias, persistent fatigue
and troublesome visceral pain, we illustrate how a frequently ignored clinical sign such as joint hypermobility can be
the keystone to clarify different simultaneous symptoms. All of the patient’s physical complaints had been investigated
separately during her previous medical examinations, and several tests repeatedly gave negative results. The patient
received different diagnoses that describe only part of her problems, such as irritable bowel syndrome for visceral pain,
fibromyalgia for arthralgias or depression for fatigue. These approaches gave rise to pharmacological or physical
treatments which did not improve her quality of life in any way and in some instances worsened the situation.
Pronounced joint hypermobility which led the patient to flex her joints excessively, causing subluxations in
several districts, was the only sign overlooked.
Conclusion: Exploring the patient’s articular features in her clinical context led us to diagnose joint hypermobility
syndrome, a complex and often ignored condition. The case highlights the utility of a multidisciplinary approach
and coordinated interventions to define and manage this clinical entity.
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Background
Joint hypermobility (JH) is defined as the ability to move
specific articular segments painlessly beyond the normal
range. A localized JH may be seen in some professions
[1], or a generalized one which usually results from a
congenital disease or acquired conditions. Whereas the
latter is common among athletes [2], congenital JH may
be an indicator of potentially threatening connective
tissue diseases, such as Marfan syndrome (MFS) or
Ehlers-Danlos syndrome (EDS) in particular, though
most patients appear with no signs of further serious
conditions.
JH is a relatively common finding (from 10 to 30 % of
children) [3] and present in addition to a wide range of
subtle symptoms such as musculoskeletal and neuropathic
pain, joint instability, fatigue or anxiety [4, 5], but also
cardiovascular autonomic diseases [6, 7] and bowel dis-
turbance [8, 9] which are usually investigated and treated
as distinct problems. JH and some of these features define
the picture of the so-called joint hypermobility syndrome
(JHS), a wide-spectrum clinical condition that is often
hard to diagnose. It is a challenge to assess the frequency
of JHS in the general population; the undefined signs, the
lack of specific laboratory findings, but also the patients’
difficulty in describing their symptoms make it easy to
underestimate or overlook this clinical picture. Moreover
the syndrome is very similar – sometimes identical - to
the more common variant of EDS hypermobility type
(EDS-HT) (rev in [10–12]).
Even though JHS presents the clinician with a substan-
tial challenge, a pivotal issue in reaching a diagnosis is
proper investigation. Hypermobility can be measured with
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a standardized method but the main problem is how to
relate hypermobile patients to the clinical entity. The
Beighton hypermobility score [13] is the most widely used
system for rating hypermobility of the peripheral joints
and spine (Fig. 1) and even if it does not consider pauci-
articular conditions or other sites, such as the foot, it can
detect the majority of cases. The Brighton criteria [14],
which incorporate the Beighton score as well as the main
symptoms and phenotypic features, are used to diagnose
JHS (Table 1). A very effective five-point questionnaire
was recently proposed by Hakim and Grahame to evaluate
JH [15] (Table 2).
Case presentation
A 20-year-old Caucasian female was referred to our out-
patient rheumatology unit for generalized arthralgia and
myalgia, associated with persistent fatigue. She reported
recurrent sprains and tendonitis in the wrists and ankles
during sport since childhood but nevertheless she prac-
ticed skiing at a competition level. In 2008, when she was
14, she had developed Raynaud’s phenomenon which was
promptly evaluated by a rheumatologist and classified as a
primary condition on the basis of a completely normal
capillaroscopy and complete blood tests. The year after
this, while the patient was in the United States, she caught
first of all SARS flu, and then Epstein-Barr virus which
resulted in a long period of persistent asthenia that kept
her bedridden for some months.
In 2010, she started physical training again, but reported
repeated musculoskeletal traumatic events, responding
poorly to physical therapy. The worst episode was a neck
trauma due to a severe skiing fall which caused an inver-
sion of the natural cervical spine lordosis. This worsened
the patient’s fatigue and aggravated the diffuse arthralgia.
Gradually the previous symptoms were joined by lower
limb paresthesia and in 2011 she was investigated for a
suspected neurological or muscle disease (brain MRI,
four-limbs EMG), but the result was negative. Also
negative was MRI of the entire spine, a total body bone
scan, and a skull and jaws X-ray carried out at short inter-
vals. She was seen twice by rheumatologists, and both
concluded with a diagnosis of fibromyalgic syndrome even
if there was no subsequent confirmation at rheumatology
control visits.
Between 2011 and 2013, the patient tried to pick up her
physical activity once more, but encountered difficulties in
running and swimming, and eventually stopped because
of the worsening of joint pain. At the same time she
complained of sleep disturbance, poor concentration and
mood depression. She was therefore examined by a neur-
ologist and after a few months she was treated with
clonazepam which did not relieve her symptoms but,
despite that she was still following the therapy when she
attended our unit. The clinical picture, diagnostic proce-
dures, therapies prescribed and their results are summa-
rized in Table 3.
At our examination in July 2014, the patient appeared in
good general condition. She complained of diffuse arthral-
gia mainly in the shoulders, ankles, wrists and knees, which
had a heavy impact on her life. She said that these symp-
toms became worse during physical effort, so she was
obliged to stop what she was doing until the symptoms
Specific joint laxity YES NO
1. Passive apposition of thumb to forearm Left Right 
2. Passive hyperextension of  V-MCP > 90° Left Right
3. Active hyperextension of elbow >10° Left Right
4. Active hyperextension of knee >10° Left Right
5. Ability to flex spine placing palms to floor without bending knees
*Each “YES” is 1 point. A score 4 out 9 is generally considered an indication of JH. (MCP: metacarpophalangeal).
Fig. 1 Beighton score for joint laxity*
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passed, causing a complete change in her lifestyle. She re-
ported a weight gain of about 15 kg in the last 8 months,
which she explained by the interruption of physical activ-
ities. She reported variable abdominal discomfort, alternat-
ing bowel and sometimes difficult urination, with dysuria
and pollakiuria although she had no urinary infections. In
addition, she described chewing problems which gave rise
to moderate pain in the temporo-mandibular joints. The
series of symptoms and functional limitations created a
feeling of frustration, though not true depression.
Her latest laboratory investigation indicated normal
blood cell count, kidney, liver and thyroid function, acute
phase reactants and C3-C4 levels. A complete autoanti-
bodies (Abs) panel (anti-nuclear Abs, anti-extractable
nuclear antigen Abs, anti-double strand DNA Abs, anti-
cardiolipin Abs and anti-neutrophil cytoplasmic Abs) was
all negative. At presentation pulmonary, cardiovascular
and abdominal examinations gave normal findings. Per-
ipheral pulses were normal. The pupils reacted normally
to light and accommodation. Superficial lymph nodes
were not detectable. Muscle tone and strength were ap-
parently within normal limits and osteo-tendinous reflexes
were present. The skin appeared thin and elastic, without
scarring.
Joint examination detected no swelling or other signs
of inflammation. Axial and peripheral joint mobility
was preserved, with widespread joint hypermobility:
she had evident extra-range mobility of the knees,
elbows, fingers (strongly hyper-extended) at both active
and passive mobilization. The patient could stretch and
twist her thoracic-lumbar spine but could also dislocate
the temporo-mandibular joint with extreme facility; she
reported she had been able to do the splits as a child.
We measured the range of motion with a goniometer
to establish the precise articular extensibility. Then we
applied a Beighton score with a result of 6/9, indicative
of joint hypermobility.
On the basis of clinical history, previous investigations
and physical examination we excluded clinical entities such
as celiac disease, fibromyalgia or other connective tissue
disorders and suggested a diagnosis of JHS as two of the
main Brighton diagnostic criteria were met (Beighton score
4/9 or more; arthralgia for longer than 3 months in four or
more joints) and the Hakim and Grahame questionnaire
(positive answers to questions 1, 2 and 3).
Conclusion
The term JHS was first used by Kirk and his group in
1967 to describe a disorder in which musculoskeletal pain
occurs in a generalized joint hypermobility substrate [16].
Most authorities now are interpreting JHS as a hereditable
connective tissue disorder - as proved by studies on twins
[17] and the role of the tenascin X gene [18]. Tenascin X,
an extracellular matrix protein, seems to be low in about
40 % of people who clinically present JH, arthralgia and
abnormal skin [18]; moreover, 5–10 % of patients diag-
nosed with JHS or EDS-HT have low serum levels of
tenascin X [18]. Despite this, virtually no genes have been
found to be strictly related to JHS - with some exceptions
of familial clusters [19].
The main feature of JHS and probably the most striking
is the ability to flex several joints well beyond the normal
range, causing subluxations to different extents. JH is rela-
tively common in certain categories of patients such as
children where the prevalence ranges from 10 to 30 % [3],
but also in adult women, who are more affected than men
[3]. Some epidemiological surveys have reported the
prevalence of generalized JHS in the general population as
from 5 to 43 % depending on the assessment criteria, age,
sex and ethnicity [3, 20–24]. Generalized JH is more
common in infancy and decreases with age; however,
musculoskeletal pain increases over time from childhood
to adolescence and through adult life [25]. Estimating the
frequency of JHS in later life is difficult because the
Table 2 Five point Hypermobility questionnaire
1. Can you now [or could you ever] place your hands flat on the floor
without bending knees?
2. Can you now [or could you ever] bend your thumb to touch your
forearm?
3. As a child, did you amuse your friends by contorting your body into
strange shapes or could you do the splits?
4. As a child or teenager, did your kneecap or shoulder dislocate on
more than one occasion?
5. Do you consider yourself “double-jointed”?
Answering yes to 2 or more of these questions suggests hypermobility
(sens 85 %, spec 90 %)
Table 1 Revised Brighton diagnostic criteria
Major Criteria
1. Beighton score of 4/9 or greater
2. Arthralgia for more than 3 months in 4 or more joints
Minor Criteria
1. A Beighton score of 1, 2 or 3/9 (0 to 3 if over age 50)
2. Arthralgia for more than 3 months in 1–3 joints, or back
pain≥3 months, or spondylosis, spondylolysis, spondylolisthesis
3. Dislocation or subluxation in more than one joint, or in one joint
on more than one occasion
4. Soft tissue rheumatism in 3 or more locations (eg, epicondylitis,
tenosynovitis, bursitis)
5. Marfanoid habitus
6. Abnormal skin (eg, striae, hyperextensible, thin, or papyraceous scarring)
7. Eye abnormalities (eg, drooping eyelids, myopia, anti mongoloid slant)
8. Varicose veins or hernia or uterine/rectal prolapse
JHS is diagnosed in three cases, if present: I) Two major criteria; II)
One major and two minor criteria; III) Four minor criteria. The disorder
is excluded in those patients with MFS or EDS.
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diagnosis is complicated by physiological changes in
connective tissue extensibility during aging. This markedly
reduces articular hyper-extension, masking the syndrome.
This explains why some studies report a JHS frequency
similar to a rare disease (1/5000) [26] while recent findings
suggest a significant increase in the prevalence that could
affect from 0.75 to 2 % of the general population [27].
The clinical picture of JHS involves variable manifesta-
tions mainly but not exclusively in the musculoskeletal
system, and evolving over the person’s lifetime. Trauma,
pregnancy or any condition that obliges the patient to
remain bedridden for any length of time can trigger the
onset of the syndrome - as in our patient whose symp-
toms worsened after two consecutive infections and a
neck trauma.
Even if arthralgias and myalgias are the most common
pain presentation in young adults [25], frequently there
are also cramps, enthesopathies, tendonitis, synovitis, bur-
sitis and fasciitis [28]. Generalized muscle hyperalgesia, a
true fibromyalgic syndrome or a chronic pain syndrome
are common additional features (rev in [12]). Our patient
had had joint instability since childhood (ability to do the
splits, patellar instability, recurrent sprains to hands and
ankles) but only in adolescence complained of progressive
musculoskeletal disorders, in the form of recurrent ten-
donitis, joint instability, diffuse myalgias and pain that led
to the diagnosis of fibromyalgia at first and subsequently
to the suspicion of neurological or primary muscle disease.
The pathogenesis of musculoskeletal pain can be related
to joint instability which facilitates repeated microtrauma
to articular and periarticular structures [28]. The laxity of
tendino-ligamentous tissues produces a lack of muscle
tone which causes defective proprioception and muscle
deconditioning [29]. This is closely related to the impaired
body image perception which leads to wrong postures, ag-
gravating the damage to the musculoskeletal apparatus
during everyday life and sport [28].
Even though this pathological circuit seems pivotal to
the rise and establishment of muscular symptoms, a sub-
sequent centralization of pain has been recently suggested
in JHS patients [12]. Dysesthesias and peripheral paresthe-
sias are recurrent complaints [30], such as our patient had
developed during the last few months before our evalu-
ation. Skin laxity is a frequent clinical sign [14, 31] and
can be demonstrated by exceptional extensibility on the
dorsum of the hands or on the elbows.
Fatigue and faintness are other common findings in
the widespread clinical picture of JHS [32] that strongly
Table 3 Timeline of patient clinical history, diagnostic procedures and therapeutic programs
Abbreviations: Abs autoantibodies, ANA anti-nuclear Abs, ENA anti-extractable nuclear antigen Abs, a-dsDNA anti-double strand DNA Abs, a-CL anti-cardiolipin Abs,
a-B2GPI anti-B2 glicoprotein I Abs, ANCA anti-neutrophil cytoplasmic Abs, a-tTGA anti-tissue transglutaminase Abs, RF rheumatoid factor, MRI magnetic resonance
imaging, EMG electromyography, NSAID non steroideal antinflammatory drugs, Complete blood tests refers to: blood cell count, liver and kidney function, serum
electrolytes, serum protein electrophoresis, acute phase reactants, serum IgA, IgM and IgG levels, thyroid function, urine analysis; QoL quality of life
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limit physical activities, with a heavy impact on everyday
life - as in our case. In fact, it has been recently reported
that 84 % of JHS patients (mostly females) present weak-
ness but the physiopathological basis remains elusive up
to the present day [32]. Sleep disturbance [4, 32], poor
postural control with consequent anti-gravitational
muscle over-activation and in some cases autonomic al-
terations (palpitation, postural orthostatic hypotension
and tachycardia) [6, 33, 34] have been suggested as pos-
sible concomitant causes of asthenia in affected people.
JHS is also frequently associated with visceral pain and
gastrointestinal disturbance [8, 9]. For instance, our pa-
tient sometimes alternates several episodes of diarrhea
in a day with some days of complete constipation, when
she suffers abdominal discomfort. The pathogenesis of
the visceral pain and the dysfunctional features is less
understood, though weakness in the supporting struc-
tures, such as the abdominal wall and pelvic floor, are
probably responsible for visceral ptosis, elongation and
abnormal dilatation which may be the anatomical coun-
terparts of a more complex functional gastrointestinal
derangement [12].
Diagnosing JHS may pose a real challenge for the clin-
ician who is not familiar with the numerous manifesta-
tions of this syndrome. The clinical manifestations go
beyond the confines of the musculoskeletal system [10].
The main presenting complaints are nociceptive pain
such as arthralgias, myalgias and back pain [25], often
associated with a history of sprains and joint instability.
Other features are abdominal pain [8, 9], headache [34],
fatigue [32] but also dysmenorrhea, fibromyalgia and
sleep disturbance [4, 32].
It is essential to read between the lines of complaints
to distinguish other clinical situations and even psychi-
atric conditions such as hypochondria. Diseases that
have generalized joint laxity as a clinical feature, like
MFS or EDS, must be included in the differential diag-
nosis of JHS but each of these disorders has several
features which distinguish it from JHS. An exception is
the EDS-HT subtype which has almost the same
clinical spectrum; in fact, these two conditions are
sometimes considered as different degrees of the same
syndrome [10].
The fact that this syndrome is not well known may
result in unnecessary examinations and harmful treat-
ments. Our patient was prescribed clonazepam for more
than a year with no useful results. She also had standard
physiotherapy which only worsened the condition. For
these reasons JHS is not only a significant cause of
discomfort for patients but also a great challenge for
clinicians and a heavy burden on health systems. A use-
ful approach to detect JHS promptly in patients with
arthralgia, prone to recurrent articular injuries, could be
based on correct administration of the Hakim and
Grahame questionnaire (Table 2) as a first step, followed
by the Brighton diagnostic criteria (Table 1).
The management of JHS can be very challenging and is
currently hampered by the paucity of large cohort com-
parative data on treatments [3, 12, 35]. While judicious
use of non-steroidal anti-inflammatory drugs can be useful
to relieve joint and muscle pain, non-pharmacologic
interventions are the core in the management of joint
hypermobility and JHS [36]. A physiotherapist with special
interest in joint hypermobility is recommended for patient
education, strengthening exercises, core stability, teaching
posture, joint protection and selected use of braces and
orthoses [27]. A podiatric assessment is also suggested to
improve biomechanical and support of the feet. Very
useful recommendations for the management of musculo-
skeletal pain and fatigue in JHS were recently published
by Castori et al. [12]. Nevertheless, it is cardinal import-
ance for clinicians to refer these patients to specialized
centers where a multidisciplinary approach and a patient
education program can be applied to treat the various
manifestation of the syndrome. Some useful information
for readers can be found in HMSA (http://hypermobili-
ty.org) and EDSUK (www.ehlers-danlos.org) support
groups.
Our patient was referred to a specialized hypermobility
unit in the city where she was studying. The diagnosis
was confirmed and the patient was placed in a coordi-
nated program of physiotherapy, pain management and
podiatry. Treatment focused on regaining muscle tone
and improving proprioception without excessive joint
stress. At more than 1 year treatment is still in progress
and the patient reported a considerable positive impact
on her quality of everyday life even after the few first
sessions of physical reconditioning.
In conclusion, this case report highlights the clinical
complexity and the multidisciplinary importance of JHS,
an unexpectedly common disease that still tends to be
under-recognized. Early diagnosis is essential to avoid long
and often unnecessary diagnostic paths and to define not
only the chronic pain but also the complex systemic
symptoms that often characterize the syndrome. Manage-
ment of JHS is equally intricate and requires a coordinated
intervention that includes patient education, personalized
physiotherapy and multidisciplinary medical collaboration.
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